Cantourage Group SE

Research Updates

Christian Sandherr

06 Dec 24

Full steam ahead, FY24 guidance raised; PT up

Update
Christian Sandherr

10 Oct 24

9M prelims: Growth further accelerating, FY guidance specified

Preview / Review
Christian Sandherr

05 Sep 24

FY24 guidance issued, growth to remain stellar

Update
Christian Sandherr

28 May 24

Debottlenecking production capacities

Update
Christian Sandherr

17 May 24

Solid FY23 and Q1'24 prelims // accelerating growth in April; chg.

Preview / Review
Christian Sandherr

06 Feb 24

Cannabis legalization around the corner

Update
Christian Sandherr

21 Nov 23

Continued strong growth in Q3; chg.

Preview / Review
Christian Sandherr

25 Oct 23

Entering the Swiss medical cannabis market

Update
Christian Sandherr

06 Sep 23

Own telemedicine platform to ease prescription hurdles; chg.

Update
Christian Sandherr

21 Jul 23

Strong H1 prelims // legislative tailwinds forming

Update
Christian Sandherr

22 May 23

Strong Q1 prelims // FY profitability in reach; Up to BUY

Update

Downloads

Latest Research
Initiation

Analyst

Christian Sandherr

Equity Research

MailLinkedIn

Latest News

19.12.2024 08:00:19
EQS-News: Cantourage Group SE exports medical craft cannabis for the first time to the growth market of Poland; cooperation with the wholesaler PharmaVitae to be expanded in 2025
06.12.2024 09:01:01
Original-Research: Cantourage Group SE (von NuWays AG): BUY
20.11.2024 08:00:21
EQS-News: New Sales Record: Cantourage Group SE Reports EUR 5.5 Million in Revenue for October 2024, Reaffirming Full-Year Growth Targets
07.11.2024 08:00:16
EQS-News: Strong EBITDA growth: Cantourage Group SE posts EBITDA of EUR 1.4 million in third quarter of 2024 and sets course for further profitable growth
10.10.2024 09:02:11
Original-Research: Cantourage Group SE (von NuWays AG): Buy

Best-in-class research on selected German and European small caps. Immediately at publication and 100% free of charge.

To learn how we process your data, visit our Privacy Notice.